Webinar: HPTN 083 Primary Study Results

The HIV Prevention Trials Network (HPTN) held a community webinar, on July 16, to present the primary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that a PrEP regimen containing CAB LA was superior to oral TDF/FTC for the prevention of HIV acquisition among cisgender men and transgender women who have sex with men.

Host: Melissa Turner, HPTN Community Working Group Chair

Moderator: Mitchell Warren, Executive Director, AVAC

Panelists:

• HPTN 083 Protocol Chair - Dr. Raphael Landovitz, UCLA Center for Clinical AIDS Research and Education (CARE)
• HPTN 083 Protocol Co-Chair - Dr. Beatriz Grinsztejn, National Institute of Infectious Diseases Evandro Chagas-

Additional panelists avialbe for questions and answer session:

• HPTN 084 Protocol Chair - Dr. Sinead Delany-Moretlwe, Wits RHI, University of Witwatersrand
• HPTN 084 Protocol Co-Chair - Dr. Mina Hosseinipour, UNC Project Lilongwe
• Head of Research & Development, ViiV Healthcare – Dr. Kimberly Smith
• Senior Director, Global HIV Prevention Strategy, ViiV Healthcare – Dr. Alex Rinehart

Watch the recording here.